An absolutely packed Metabologia Spotlight session underway #easd2026 with Editor Jennifer Sargent, and Associate Editors Nicholas Chew, Sara Suliman and Sami Qadri

Today at #EASD2026, we're seeing quite a study in contrasts. Between potency and tolerability, between retatrutide and petrelintide. One size fits none.
HT: @thelancet.com @thelancetendo.bsky.social @nejm.org
conscienhealth.org/2026/09/30/e...

The giant exhibition hall at #EASD2026. This only captures a fraction of it but highlights the content more by what is missing i.e. insulin. Lots on GLP1s. The Age of T1D focus is coming to an end and the age of obesity management begins.#dedoc⁰

Interestingly, the risk difference only applies if the mother had T1D during pregnancy, otherwise the risk is the same as paternal T1D. T2D does not offer the same reduced risk suggesting it is not exposure to high blood sugar. #EASD2026 #dedoc⁰

Having a father or siblings with T1D leads to double the risk of getting T1D compared to having a mother with T1D #EASD2026 #dedoc⁰

Daniah population study looking at how relative history of allergy, auto-immune, T1D, and T2D leads to a risk of developing T1D. Allergy history not as strong but the others are very significant. #EASD2026 #dedoc⁰

In our 2026 special issue: Imaging of #MASLD: clinical standards and novel methods link.springer.com/article/10.1... Pick up a print copy at #EASD2026

On the spotlight stage today 12-12.45 #easd2026 Metabologia symposium The emerging cardiovascular-kidney-liver-metabolic (CKLM) interplay: from population health to targeted therapies. Chaired by editor Jennifer Sargent, and panellists from the journal’s editorial board

🔴 Happening now at #EASD2026.

Today's session draws on insights from a major Phase 3 efficacy trial: TRIUMPH-2 of retatrutide in people with obesity & T2D with:
🎤 John Wilding
🎤 Juan Pablo Frias
🎤 Elif Ekinci
🎤 Elisabeth Van Rossum

Chaired by Arya M. Sharma

📍 Happening now in the Paris Hall

Visiting the Member Lounge at #EASD2026? The @EASOobesity stand is just next door!

We’re #31 in the EASD Community Plaza on level 0- please come by to learn what’s on ! #ECO2027 abstracts are open

Come il trasloco in un nuovo quartiere può influenzare il rischio di diabete di tipo 2 #EASD2026

Secondo una nuova ricerca canadese presentata al congresso annuale dell'Associazione Europea per lo Studio del Diabete (EASD) a Milano (28 settembre - 2 ottobre), l'area geografica in cui una persona…

In our 2026 special issue: Screening and diagnosis of #liverdisease in #diabetes: a guide and evidence-based assessment link.springer.com/article/10.1... Pick up a print copy at #EASD2026

Metabologia wants your research papers on the #metabolic aspects of #diabetes, #obesity, #CVD and #renal and #hepatic disease #comorbidity #nutrition #exercise #psychosocial #healtheconomics #healthtechnology – submit now! metabologia.org #EASD2026

Sten Madsbad & Jens J Holst comment on:
Petrelintide and the evolving role of amylin agonism in obesity thelancet.com/journals/lan...
#obesity
#EASD2026

#MedSky #EndoSky

New—Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial thelancet.com/journals/lan...
#obesity
#EASD2026

#MedSky #EndoSky

❤️ On #WorldHeartDay, we welcomed Commissioner OliverVarhelyi to our Know Your Numbers Mobile Unit at #EASD2026 following the European Commission’s publication of its Proposal for a Council Recommendation on cardiovascular health checks.

Meet the incoming Editor! Patrick Schrauwen will be at the Diabetologia/Metabologia stand to answer your questions Wednesday 11.30 CEST diabetologia-journal.org #EASD2026

In our 2026 special issue: #MASLD prevalence, incidence and global aspects link.springer.com/article/10.1... Pick up a print copy at #EASD2026

Are you attending #EASD2026? Don't miss the KDIGO session on Thursday, 1 October, from 12:30 - 14:00.

The session will highlight current and forthcoming KDIGO work on the interconnected challenges of diabetes, kidney disease, and cardiovascular health.

Please stop by the KDIGO booth to say hello!

New—Disease modification outcomes in type 2 #diabetes: a modified Delphi thelancet.com/journals/lan...
#T2D
#EASD2026

#MedSky #EndoSky